KRAS and non-small cell lung carcinoma: Five trials examined the impact of PD-L1 or PD-1 inhibitors in patients with NSCLC who had a KRAS mutation or were wild-type (four with hazard rate of OS and three with hazard rate of PFS) [21, 25–28].